ArticleOncogene2002
Lung-specific expression of human mutant p53-273H is associated with a high frequency of lung adenocarcinoma in transgenic mice.
Article in Oncogene, 2002. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 31 citations in OpenAlex.
- Mutant p53 in cancer: from molecular mechanism to therapeutic modulation.Cell death & disease · 2022Review
- The oncogenic potential of a mutant TP53 gene explored in two spontaneous lung cancer mice models.BMC cancer · 2020Article
- Mutant p53 in cancer therapy-the barrier or the path.Journal of molecular cell biology · 2019Review
- Homologous recombination defects and how they affect replication fork maintenance.AIMS genetics · 2018Review
- TP53 oncomorphic mutations predict resistance to platinum‑ and taxane‑based standard chemotherapy in patients diagnosed with advanced serous ovarian carcinoma.International journal of oncology · 2015Article
- OncomorphicJournal of cancer therapy · 2014Article
- Mutant p53 gain-of-function in cancer.Cold Spring Harbor perspectives in biology · 2010Review
- 20 years studying p53 functions in genetically engineered mice.Nature reviews. Cancer · 2009Review
- Expression of a mutant p53 results in an age-related demographic shift in spontaneous lung tumor formation in transgenic mice.PloS one · 2009Article
- A mouse model for EML4-ALK-positive lung cancer.Proceedings of the National Academy of Sciences of the United States of America · 2008Article
- Lung specific expression of a human mutant p53 affects cell proliferation in transgenic mice.Transgenic research · 2008Article
- p53 dominant-negative mutant R273H promotes invasion and migration of human endometrial cancer HHUA cells.Clinical & experimental metastasis · 2007Article
- Cancer stem cells: the lessons from pre-cancerous stem cells.Journal of cellular and molecular medicineReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
To investigate the tumorigenic potential of mutant p53 when selectively expressed in lung tissue, a transgenic mouse model was developed in which a mutant form of p53 (p53-273H) was placed under the transcriptional control of the lung-specific human surfactant protein C (SP-C) promoter. Two founder mice were identified, and a line of SP-C/p53-273H transgenic mice was established from one of the founders. Human p53-273H protein was detected specifically in lung tissue from transgenic mice. Malignant tumors, which were histologically characterized as adenocarcinomas, were observed in transgenic mice, with the earliest onset documented at 4 months of age. To further evaluate incidence and onset of tumor formation, transgenic mice (n=113) were sacrificed at age intervals ranging from 4-15 months. At 13-15 months of age, transgenic mice were significantly more likely to have lung tumors at necropsy than age-matched non-transgenic littermates (9 out of 39 (23%) versus 2 out of 35 (5.7%), chi(2) test, P=0.036). The SP-C/p53-273H transgenic mice described here thus represent a genetically defined model with which to study the role of p53 mutations in lung tumorigenesis, as well as the potential complementary contributions of other genetic alterations or environmental carcinogens to lung tumor development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.